Protocols

Lilly, Incyte’s baricitinib wins fast-track status for hard-to-treat lupus; Synthorx hammers out $150M+ IPO

→ Rheumatoid arthritis drug Olumiant — approved for a narrower-than-expected patient population earlier this year to the dismay of its manufacturer Eli Lilly $LLY and Incyte $INCY which had blockbuster dreams for the drug — may be worth its weight in gold if approved for lupus, a disease in which the immune system attacks its host, and has seen a solitary approved treatment in the last 50 years. The companies announced on Thursday that the drug, known chemically as baricitinib, had been granted fast-track status by the FDA for lupus. Two doses of baricitinib, which is also being investigated as a treatment for atopic dermatitis, are currently in Phase III trials in patients with systemic lupus erythematosus.

→ Avalon-controlled Nektar $NKTR rival Synthorx $THOR — which began trading on December 7 — has closed its IPO of about 13.7 million shares priced at $11 per share. Gross proceeds from the offering were about $150.7 million, the La Jolla, CA-based company said on Wednesday.

→ Novartis $NVS and Roche’s blockbuster biologic Xolair, which is approved for hives as well as allergic asthma, is vulnerable to competition after losing patent protection, with a few competitors working on biosimilars. Originally approved as an injectable prescription medicine, the drug is also available in certain regions as a liquid formulation. Novartis, on Thursday, announced the EC had granted the company approval for a pre-filled syringe of Xolair for self-administration, potentially reducing the number of regular clinic visits a patient would have previously undertaken.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,400+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->